Treatment of Epiretinal Membranes With Ranibizumab

Sponsor
Queen's University
Study ID
NCT01238393
Status
Completed

Conditions

  • Epiretinal Membrane

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Key Dates

First listed
Nov 10, 2010
Start date
Nov 30, 2010
Status verified
Jan 2016
Primary completion
Nov 30, 2011
Completion
Jan 31, 2012

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab
    ('intravitreal ranibizumab' )

Primary Outcome Measure

Evidence of improvement measured by optical coherence tomography [ Time Frame: 3 and 6 months ]

Related Studies